Yahoo
OTC Markets OTCPK - Delayed Quote USD

Appili Therapeutics Inc. (APLIF)

0.0070 0.0000 (0.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for APLIF
  • Previous Close 0.0070
  • Open 0.0040
  • Bid 0.0040 x 3500000
  • Ask 0.0070 x 3400000
  • Day's Range 0.0040 - 0.0068
  • 52 Week Range 0.0040 - 0.0200
  • Volume 36,649
  • Avg. Volume 5,493
  • Market Cap (intraday) 926,562
  • Beta (5Y Monthly) 0.14
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

appilitherapeutics.com

7

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

APLIF
56.25%
S&P/TSX Composite index (^GSPTSE)
11.78%

1-Year Return

APLIF
53.33%
S&P/TSX Composite index (^GSPTSE)
18.03%

3-Year Return

APLIF
75.86%
S&P/TSX Composite index (^GSPTSE)
88.90%

5-Year Return

APLIF
98.86%
S&P/TSX Composite index (^GSPTSE)
69.32%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY24
Revenue 483.98k
Earnings -152.34k
Profit Margin -31.48%

Q4

FY23

Q1

FY24

Q2

FY24

Q3

FY24

-2M
-1M
0
-15000.0%
-10000.0%
-5000.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -255.65%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    362.07k

  • Net Income Avi to Common (ttm)

    -4.69M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    138.68k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.54M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: